4.6 Article

Bone geometry in older adults with subclinical hypothyroidism upon levothyroxine therapy: A nested study within a randomized placebo controlled trial

期刊

BONE
卷 161, 期 -, 页码 -

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bone.2022.116404

关键词

Levothyroxine; Subclinical hypothyoroidism; Peripheral quantitative computational tomography; Bone geometry; Volumetric bone density

资金

  1. Swiss National Science Foundation [SNSF 320030-150025, 320030-172676, 32003B_200606, PZ00P3-167826]
  2. European Union FP7HEALTH-2011 program [278148]
  3. Swiss Heart Foundation
  4. Velux Stiftung [974a]
  5. Swiss Society of Endocrinology and Diabetes
  6. Leenaards Foundation
  7. Vontobel Foundation
  8. European Commission project THYRAGE (Horizon 2020 Research And Innovation Program) [666869]
  9. ZonMw [627001001]
  10. Swiss National Science Foundation (SNF) [32003B_200606] Funding Source: Swiss National Science Foundation (SNF)
  11. H2020 Societal Challenges Programme [666869] Funding Source: H2020 Societal Challenges Programme

向作者/读者索取更多资源

This study investigated the effect of levothyroxine (LT4) therapy on appendicular bone geometry and volumetric density in patients with subclinical hypothyroidism. The results showed that LT4 therapy had no significant effect on bone mass, bone geometry, and volumetric density in older adults with subclinical hypothyroidism.
The effect of levothyroxine (LT4) therapy for subclinical hypothyroidism (SHypo) on appendicular bone geometry and volumetric density has so far not been studied. In a nested study within the randomized, placebocontrolled Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) trial, we assessed the effect of LT4 therapy on bone geometry as measured by peripheral quantitative computed tomography (pQCT). In the TRUST trial, community-dwelling adults aged >= 65 years with SHypo were randomized to LT4 with dose titration vs. placebo with mock titration. We analyzed data from participants enrolled at the TRUST site in Bern, Switzerland who had bone pQCT measured at baseline and at 1 to 2 years follow-up. The primary outcomes were the annual percentage changes of radius and tibia epi- and diaphysis bone geometry (total and cortical crosssectional area (CSA) and cortical thickness), and of volumetric bone mineral density (bone mineral content (BMC) and total, trabecular and cortical volumetric bone mineral density (vBMD)). We performed linear regression of the annual percentage changes adjusted for sex, LT4 dose at randomization and muscle crosssectional area. The 98 included participants had a mean age of 73.9 (+/- SD 5.4) years, 45.9% were women, and 12% had osteoporosis. They were randomized to placebo (n = 48) or LT4 (n = 50). Annual changes in BMC and vBMD were similar between placebo and LT4-treated groups, without significant difference in bone geometry or volumetric bone mineral density changes, neither at the diaphysis, nor at the epiphysis. For example, in the placebo group, epiphyseal BMC (radius) decreased by a mean 0.2% per year, with a similar decrease of 0.5% per year in the LT4 group (between-group difference in %Delta BMC 0.3, 95% CI -0.70 to 1.21, p = 0.91). Compared to placebo, LT4 therapy for an average 14 months had no significant effect on bone mass, bone geometry and volumetric density in older adults with subclinical hypothyroidism. Trial registration: The trial was registered on ClinicalTrials.gov numbers NCT01660126 (TRUST Thyroid trial) and NCT02491008 (Skeletal outcomes).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据